Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 proof-of-concept study in FGFR1/FGFR2-amplified tumors
2011-003718-18Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fexagratinib in breast cancer, bronchial carcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Correlation of antitumor activity with molecular FGFR pathway changes. Started Nov 2011; status: completed.
02
Drugs
fexagratinib
03
Conditions
breast cancerbronchial carcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2011-003718-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003718-18.